New pill hopes to fight Hard-to-Treat cancers
NCT ID NCT05142592
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental oral drug called IPG7236 in people with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, then expanding to see if the drug can control tumor growth. About 196 participants will take the pill twice daily in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPG7236 (oral tablet)
What this could lead to
If it works, this could point toward a new oral treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early, first-in-human trial with only 196 participants. The drug may not shrink tumors or could cause unexpected side effects. Success in early phases does not guarantee later approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGAustin, Texas, 12221, United States
Contact
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97222, United States
Contact
-
Shandong Cancer Hospital
RECRUITINGJinan, Shangdong, China
Contact
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact
-
Shanghai General Hospital
ACTIVE_NOT_RECRUITINGShanghai, China
-
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITINGShanghai, China
Contact
-
The First Affiliated Hospital Nanchang Univeristy
RECRUITINGNanchang, Jiangxi, China
Contact